Journal: Journal of clinical and translational hepatology
This publication presents a consensus developed by the Chinese Society of Hepatology on managing liver injury caused by molecular targeted therapies and immune checkpoint inhibitors in hepatocellular carcinoma (HCC) patients.
It reviews adverse liver reactions associated with these systemic treatments and summarizes current diagnostic and therapeutic advances both in China and internationally.
The guidance offers practical recommendations to:
- Monitor liver injury during targeted and immunotherapy
- Diagnose liver injury effectively
- Prevent liver injury
- Treat liver injury promptly
The goal is to optimize clinical decision-making and improve patient outcomes in HCC management.